Megakaryocytes are highly specialized cells that arise from a bipotent megakaryocytic-erythroid progenitor (MEP). This developmental leap requires coordinated activation of megakaryocyte-specific genes, radical changes in cell cycle properties, and active prevention of erythroid differentiation. These programs result from upregulation of megakaryocyte-selective transcription factors, downregulation of erythroid-selective transcription factors and ongoing mediation of common erythro-megakaryocytic transcription factors. Unlike most developmental programs, no single lineage-unique family of master regulators exerts executive control over the megakaryocytic plan. Rather, an assemblage of non-unique factors and signals converge to determine lineage and differentiation. In human megakaryopoiesis, hereditary disorders of platelet production have confirmed contributions from three distinct transcription factor families. Murine models have extended this repertoire to include multiple additional factors. At a mechanistic level, the means by which these non-unique factors collaborate in the establishment of a perfectly unique cell type remains a central question.
Megakaryocytes are highly specialized cells that arise from a bipotent megakaryocytic-erythroid progenitor (MEP). This developmental leap requires coordinated activation of megakaryocyte-specific genes, radical changes in cell cycle properties, and active prevention of erythroid differentiation. These programs result from upregulation of megakaryocyte-selective transcription factors, downregulation of erythroid-selective transcription factors and ongoing mediation of common erythro-megakaryocytic transcription factors. Unlike most developmental programs, no single lineage-unique family of master regulators exerts executive control over the megakaryocytic plan. Rather, an assemblage of non-unique factors and signals converge to determine lineage and differentiation. In human megakaryopoiesis, hereditary disorders of platelet production have confirmed contributions from three distinct transcription factor families. Murine models have extended this repertoire to include multiple additional factors. At a mechanistic level, the means by which these non-unique factors collaborate in the establishment of a perfectly unique cell type remains a central question. Oncogene (2007) 26, 6795-6802; doi:10.1038/sj.onc.1210762 Keywords: megakaryocyte; platelet; development; transcription factor Discordant offspring from a mutually endearing parent (MEP): erythro-megakaryocytic divergence Megakaryocytic differentiation begins with the bipotent megakaryocytic-erythroid progenitor (MEP), an entity whose existence was inferred from in vitro clonal hematopoietic differentiation assays (Debili et al., 1996) and confirmed through prospective cellular isolation (Akashi et al., 2000; Manz et al., 2002) . The MEP may arise from either a committed common myeloid progenitor (CMP) (Akashi et al., 2000) or directly from a more primitive, uncommitted short-term hematopoietic stem cell (ST-HSC) (Adolfsson et al., 2005) , by an unknown mechanism that may involve programming by the transcription factor GATA-1 (Stachura et al., 2006) . The further development of MEP into megakaryocytes and erythroblasts represents probably the most striking example of sibling divergence in developmental biology. Megakaryocytes pursue a 'hypertrophic' pathway, encompassing vast cellular enlargement, acquisition of polyploidy and the elaboration of several unique cytoplasmic membranous structures. Erythroblasts opt for an 'atrophic' pathway characterized by cellular shrinkage, cytoplasmic simplification with jettisoning of several organelles, and a highly focused, almost single-minded, gene expression program. Underlying this phenotypic divergence lies an array of transcription factors, some of which are restricted to either lineage, but many of which are shared by both lineages (Figure 1 ). Further complicating this picture, most of these transcription factors subsume multiple tasks, repressing or activating a repertoire of target genes that shifts as a function of lineage and stage.
Insights into individual players in this process have been gained from comparisons of megakaryocytic and erythroid promoter/enhancers, from identification of genetic defects in human hereditary disorders of megakaryopoiesis and from mouse genetics, both targeted and random. The major challenge consists of developing and validating an integrated model for the cooperative function of these various factors as they collaborate in programming megakaryopoiesis.
GATA and Friend in sickness and in health: X-linked thrombocytopenia
A canonical feature of megakaryocytic promoters is the presence of binding sites for the GATA family of zincfinger transcription factors: WGATAR. Clinical relevance for one of these sites is illustrated in a patient with Bernard-Soulier syndrome (macrothrombocytopenia, decreased platelet expression of the gpI-IX-V complex and decreased platelet aggregation in response to ristocetin) in whom a GATA binding site within the glycoprotein Ibb promoter underwent mutation (Ludlow et al., 1996) . GATA-1 and GATA-2 represent the major GATA proteins expressed during erythro-megakaryocytic differentiation, with GATA-1 levels increasing and GATA-2 levels decreasing during the differentiation of both lineages (Cantor and Orkin, 2002) . Coexpressed with these GATA factors is FOG1, a large multifinger protein serving as a dedicated GATA coregulator. Mouse knockouts have implicated GATA-1 and FOG1 specifically in erythroid and megakaryocytic development; GATA-2 by contrast contributes to the proliferation of multipotent progenitors (Cantor and Orkin, 2002) .
Experiments of nature have provided glimpses of the role of GATA-1 in human megakaryopoiesis. As many as four distinct biochemical classes of GATA-1 mutation have been found in human X-linked disorders of megakaryocyte development (Liew et al., 2005) . The first class of mutations comprises N finger amino acid substitutions which impair FOG1 binding, two examples of which have been reported: V205M and G208S (Nichols et al., 2000; Mehaffey et al., 2001) . The second class involves N-finger substitutions which preserve FOG1 binding but impair binding to a DNA GATC motif found within paired GATA target sites: examples are R216Q and R216W (Yu et al., 2002; Phillips et al., 2007) . The third class also affects the N finger but disrupts neither FOG1 nor DNA binding: D218G (Freson et al., 2001; Liew et al., 2005) . The biochemical defect in this third class thus remains mysterious. An interaction potentially affected by this, or other, N-finger substitutions could be the recently described binding of the mediator complex to the GATA-1 N finger (Stumpf et al., 2006) . The fourth class of hereditary GATA-1 mutation causes congenital expression of GATA-1s, an amino terminally truncated form lacking the first 83 amino acids (Hollanda et al., 2006) .
The disease phenotypes reveal influences from both the site of substitution and the severity of loss of biochemical function. As an example of the latter influence, megakaryopoiesis displays greater sensitivity than erythropoiesis to decrements in GATA-1 binding to FOG1. In particular, the V205M mutant shows greater loss of FOG1 binding than G208S, and patients with V205M have severe anemia and thrombocytopenia, whereas those with G208S have only severe thrombocytopenia with no anemia. As an example of the site influence, substitutions of R216 affecting DNA binding produce moderate thrombocytopenia associated with a thalassemic type of anemia (Raskind et al., 2000; Yu et al., 2002; Phillips et al., 2007) . The D218G mutation, affecting neither FOG1 nor DNA binding, has been associated with moderate to severe thrombocytopenia in the absence of anemia, but the more structurally disruptive substitution D218Y resulted in severe thrombocytopenia and anemia, again suggesting that megakaryopoiesis is more sensitive than erythropoiesis to diminished GATA-1 function (Freson et al., 2001 (Freson et al., , 2002 . The single kindred identified with a mutation causing GATA-1s surprisingly displayed macrocytic anemia with normal platelet counts; however, platelet morphology and function were abnormal (Hollanda et al., 2006) . A fascinating feature shared by various kindreds with GATA-1 mutations is a role reversal in the erythro-megakaryocytic divergence, the erythroblasts showing enlargement with multinucleation and the megakaryocytes developing as small cells with hypolobulated nuclei, 'micromegakaryocytes' (Nichols et al., 2000; Freson et al., 2001 Freson et al., , 2002 Hollanda et al., 2006; Phillips et al., 2007) .
Multiple themes emerge from a survey of the human and murine GATA-1 mutant phenotypes: (1) GATA-1 plays crucial roles in both megakaryopoiesis and erythropoiesis, roles that cannot be fulfilled by GATA-2 despite structural and biochemical similarities; (2) distinct structural elements within GATA-1 contribute to distinct aspects of the differentiation program, a finding confirmed in ex vivo megakaryocytic rescue assays (Kuhl et al., 2005; Muntean and Crispino, 2005) ; (3) megakaryopoiesis depends more on GATA-1 dosage than does erythropoiesis, a finding also supported by ex vivo rescue assays (Stachura et al., 2006) ; (4) proper segregation of the 'hypertrophic' and 'atrophic' phenotypes during erythromegakaryocytic divergence relies on the activity of GATA-1. The CBF family of transcription factors comprises three homologous DNA binding proteins, RUNX1-3, and a non-DNA binding component CBFb. The complex of RUNX1 with CBFb participates in programming hematopoietic ontogeny and represents the most common mutational target in human acute leukemias (Tracey and Speck, 2000) . RUNX1 and CBFb retain high expression during megakaryocytic differentiation of MEP but undergo extinction during early phases of erythroid differentiation (Kundu et al., 2002; Elagib et al., 2003; Lorsbach et al., 2004) . Mature megakaryocytes express strikingly high levels of RUNX1 and low levels of RUNX3 (Levanon et al., 2001) . Inducible inactivation in mice of either RUNX1 or CBFb causes rapid and profound disruption of megakaryocytic differentiation, with minimal impact on erythropoiesis (Ichikawa et al., 2004; Growney et al., 2005; Kuo et al., 2006; Putz et al., 2006) . In addition, mice bearing hypomorphic CBFb alleles show defective megakaryopoiesis, confirming the lineage to be sensitive to the dosage of core binding factor (Talebian et al., 2007) .
Despite the variety of RUNX1 mutations associated with the autosomal dominant FPD/AML, most kindreds show similar clinical manifestations, in contrast to the phenotypic-genotypic correlations seen with GATA-1 mutations. Thus FPD/AML appears to result from a simple haploinsufficient dosage effect, although a dominant negative function has been suggested for some of the mutant RUNX1 alleles (Michaud et al., 2002; Matheny et al., 2007) . A central clinical feature of this disorder consists of a bleeding tendency greatly out of proportion to the mild thrombocytopenia (Dowton et al., 1985) . Platelet abnormalities include diminished dense core granules and decreased cellular adenosine diphosphate (ADP) levels (Buijs et al., 2001; Michaud et al., 2002) . Functionally, the platelets show marked aggregation defects in response to collagen, epinephrine and arachidonic acid but retain responsiveness to ristocetin (Ho et al., 1996; Walker et al., 2002; Heller et al., 2005) . Marrow megakaryocytic morphology has varied from reportedly normal (Song et al., 1999) to abnormal with immature-appearing megakaryocytes that are increased in number (Walker et al., 2002; Heller et al., 2005) . The greatly increased incidence of acute myeloid leukemia within affected family members may relate to abnormalities in hematopoietic stem cell (HSC) homeostasis associated with diminished RUNX1 function .
Causes for the platelet dysfunction in FPD/AML are most likely multiple. The diminished dense core granules and ADP may explain the 'aspirin like' aggregation defects consisting of an absent second wave in response to epinephrine stimulation (Ho et al., 1996) . In addition, have identified in a patient defective activation of the gpIIbIIIa integrin complex and diminished pleckstrin phosphorylation, both of which correlate with abnormally low platelet levels of the kinase PKCy. In another kindred, diminished platelet expression and signaling of c-Mpl was identified (Heller et al., 2005) . FPD/AML thus provides an insight into the unique sensitivity of human megakaryopoiesis to RUNX1 levels; GATA-1 haploinsufficiency, by comparison, causes no platelet abnormalities. The basis for this sensitivity most likely resides in the dependency of target genes, such as PKCy and c-MPL, on critical thresholds of RUNX transcriptional activity.
Role of Ets factors: Fli-1 and the Paris-Trousseau/ Jacobsen syndrome (PTS)
Ets factor binding sites, containing a core GGAA motif, occur in most megakaryocytic promoters, often adjacent to GATA sites (Deveaux et al., 1996; Bastian et al., 1999; Pang et al., 2006) . Three Ets factors directly contribute to murine megakaryocytic development: Fli-1, GABPa, and TEL1. Deletion of TEL1 within erythroid and megakaryocytic cells in the GATA-1-CRE::TEL1 f/f mouse strain causes a B50% drop in platelet counts with no effect on hemoglobin levels. Marrows from this strain also show a 5-fold increase in megakaryocytic colony forming cells (CFU-Mk) (Hock et al., 2004) . Similarly, inducible deletion of TEL1 in adult MX1-CRE::TEL1 f/f mice triggers rapid and dramatic drops in platelet counts, with no effects on hemoglobin levels (Hock et al., 2004) . Diminished GABPa expression in the enhancer trapped GABPa TP/TP strain results in a B50% decline in fetal liver megakaryocytes, as well as diminished megakaryocytic expression of gpIIb and c-Mpl (Pang et al., 2006) . FLI1 À/À mice manifest embryonic lethality with hemorrhage and diminished hematopoiesis. One group has reported megakaryocyte-selective hematopoietic abnormalities in fetal liver assays of colony formation and maturation (Hart et al., 2000) , whereas another group has found quantitative and qualitative defects in both erythroid and megakaryocytic lineages within fetal liver (Spyropoulos et al., 2000) . Thus while Fli-1 clearly contributes to normal megakaryocytic differentiation, its status as a lineage-selective transcription factor in erythro-megakaryocytic divergence remains uncertain. Functional comparisons between Fli-1 and GABPa have suggested a role for the former in activating late stage megakaryocytic markers such as gpIX and a role for the latter in programming early markers such as gpIIb (Pang et al., 2006) .
Relevance of Fli-1 to human megakaryopoiesis has been suggested from studies of a rare congenital disorder, the PTS. Two cases described in 1995 involved a mother and son with mild thrombocytopenia (BretonGorius et al., 1995) . Most of their circulating platelets had normal morphology, but B15% of the platelets showed enlargement with a solitary giant red granule, identified on electron microscopy (EM) as an abnormal alpha granule. The mother's marrow contained a 3-fold increase in megakaryocytes, many of which had micromegakaryocytic morphology. EM on the marrow paradoxically revealed abnormally small alpha granules within megakaryocytes, as well as a subset of megakaryocytes undergoing 'lysis', cytoplasmic zonation into regions devoid of organelles and regions with clusters of dilated vacuoles and caniliculi. Another subset of megakaryocytes displayed ultrastructural features associated with activated platelets. Fluorescence in situ hybridization analysis of chromosomes from both subjects identified a deletion of the distal portion of 11q, with a breakpoint at 11q23.3. Subsequent analysis of 14 patients with the related Jacobsen syndrome confirmed terminal 11q deletions, which in all cases led to hemizygous deletion of FLI1 (Hart et al., 2000) .
Further support for involvement of Fli-1 came from rescue studies in which FLI1 transduction of PTS CD34 þ cells restored several aspects of megakaryocytic differentiation, including levels of CD41, CD42 and vWF, as well as polyploidization and proplatelet formation (Raslova et al., 2004) . Characterization of megakaryopoiesis from PTS CD34 þ cells also established a basis for hemizygous deletion of FLI1 affecting development of a subset of megakaryocytes and platelets. At early stages of human megakaryocytic differentiation, FLI1 normally undergoes a phase of monoallelic expression, and during this phase hemizygous deletion of PTS yields subsets of megakaryocytes with either normal or absent Fli-1 expression (Raslova et al., 2004) . This monoallelic model thus explains both the pathogenecity of haploinsufficient FLI1 and the discrete populations of normal and abnormal megakaryocytes/platelets in PTS patients.
The ETS1 gene also undergoes deletion in PTS and potentially could contribute to megakaryopoiesis. In cultures of human CD34 þ cells, Ets-1 undergoes upregulation in megakaryocytic differentiation and downregulation in erythroid differentiation, albeit in a delayed manner (Lulli et al., 2006) ; enforced expression of Ets-1 in these cells enhances megakaryocytic and inhibits erythroid differentiation. Arguing against a direct role for Ets-1 in PTS are the lack of megakaryocytic abnormalities in ETS1 À/À mice and a low expression level in megakaryocytes, relative to Fli-1 (Raslova et al., 2004) . Nevertheless, the possibility remains that the hemizygous deletion of ETS1 could underlie some of the megakaryocytic abnormalities in PTS, particularly since FLI1À/À mice do not faithfully recapitulate all of the abnormalities.
Antagonists of megakaryopoiesis: c-Myb and p300
Three independent studies have applied whole mouse random mutagenesis to identify the transcription factor c-Myb as a potent negative modulator of megakaryopoiesis. Two of these studies employed large-scale chemical mutagenesis followed by screening of platelet levels (Carpinelli et al., 2004; Sandberg et al., 2005) . In both studies, hypomorphic alleles encoding transcriptionally compromised c-Myb mutants, when bred to homozygosity, caused marked elevation of circulating platelet levels and tissue megakaryocytes, confirming an earlier association in C-MYB À/loxP mice between diminished c-Myb levels and enhanced megakaryopoiesis (Emambokus et al., 2003) . In a third study, random transgene insertion upstream of C-MYB eliminated expression specifically within the MEP compartment (Mukai et al., 2006) , permitting assessment of the role of c-Myb in erythromegakaryocytic lineage divergence. Mice homozygous for the transgene insertion (Tg) displayed an increase in marrow CFU-Mk counterbalanced by a decrease on erythroid colony forming units, suggesting an influence of c-Myb levels on MEP fate. Further evidence derived from analysis of highly purified primary MEP cultured on OP9 stromal cells. Wild-type MEP gave rise to predominantly erythroid cells, while Tg homozygous MEP yielded mostly megakaryocytes, an effect reversible by retroviral transduction of C-MYB.
Transcriptional activation of target genes by c-Myb depends on the recruitment of the p300 coactivator via the latter's KIX domain. Notably, mice engineered with KIX-defective p300 phenocopy the c-Myb deficiency, showing striking increases in circulating platelets and marrow megakaryocytes (Kasper et al., 2002) . Genetic interaction of p300 and c-Myb in this pathway was confirmed in P300/C-MYB compound heterozygous mutant mice which showed platelet elevations analogous to these seen in both homozygous mutants. Thus, c-Myb most likely functions at the level of the MEP as a transcriptional activator that either drives erythroid lineage commitment at the expense of megakaryopoiesis or primarily blocks megakaryopoiesis and secondarily shunts cells into the erythroid pathway. Programmatic integration: discerning a megakaryocytic transcriptional network
As emphasized in the Abstract, the decision to pursue a megakaryocytic fate does not rest in the hands of any single transcription factor or family but rather results from a conversation among multiple families. Tables 1  and 2 illustrate points of phenotypic overlap among the several human diseases and mouse models discussed in this review, indicating a convergence of at least three different transcription factor families on key pathways within megakaryocytic growth and development. At a mechanistic level, this overlap highlights a number of mutually regulated target genes that contribute to the megakaryocytic program. Presented below are three examples of transcriptional cross talk likely to be important in megakaryopoiesis. GATA-1-and RUNX1-deficient organisms share several megakaryocytic abnormalities in common. Both show thrombocytopenia with increased marrow megakaryocytes. In both, the megakaryocytes display immature morphology, diminished ploidy, increased colony forming capabilities, increased proliferation and defective formation of demarcation membranes (Vyas et al., 1999; Nichols et al., 2000; Walker et al., 2002; Ichikawa et al., 2004; Growney et al., 2005; Heller et al., 2005; Hollanda et al., 2006) . Shared target genes include C-MPL, GPIba, JAK2 and GPIIb (Vyas et al., 1999; Heller et al., 2005; Kuhl et al., 2005; Muntean and Crispino, 2005; Liu et al., 2006; Xu et al., 2006) . Biochemical studies have demonstrated physical interaction and functional cooperation of these two factors in transcriptional activation of megakaryocytic promoters (Elagib et al., 2003; Xu et al., 2006) . Their crosstalk reflects a highly conserved pathway in evolution, with parallels found in the Drosophila GATA and RUNX counterparts, Serpent and Lozenge, which cooperate in the programming of hematopoietic crystal cell development (Fossett et al., 2003; Waltzer et al., 2003) . The Drosophila ortholog of FOG1, U-shaped, negatively regulates this program (Fossett et al., 2003; Waltzer et al., 2003) , raising interesting possibilities for the influence of FOG1 on the megakaryocytic cooperation of GATA-1 and RUNX1.
In vivo deficiency of Fli-1 also results in expansion of immature, hyperproliferative megakaryocytes with granule and demarcation membrane defects (BretonGorius et al., 1995; Hart et al., 2000) . Target genes of Fli-1 and GABPa that overlap with those of GATA-1 and RUNX1 include GPIba, c-MPL and GPIIb (Pang et al., 2006) . Biochemical analyses have confirmed physical and functional interaction of GATA-1 with Fli-1 (Starck et al., 2003) . Interestingly, Fli-1 and GABPa, but not the Ets factor PU.1, exert a positive effect on FOG1 complexed with GATA-1, promoting activation of the GPIIb promoter (Wang et al., 2002; Pang et al., 2006) . Thus, whether FOG1 functions as a corepressor or coactivator for GATA-1 may depend on the transcription factors and promoter milieu with which GATA-1 associates. The final example of crosstalk illustrates how three distinct transcription factors may come together to coordinate divergence of the megakaryocytic and erythroid lineages. In particular, Starck et al. (2003) identify GATA-1 interactions with Fli-1 in megakaryocytic complexes and with EKLF in erythroid complexes. As an additional dimension, Fli-1 and EKLF directly interact and cross-inhibit one another. Interaction with EKLF causes Fli-1 to expose a surface normally engaged in DNA binding, resulting in putative corepressor recruitment.
This type of binary model integrates several key features of megakaryocytic transcriptional regulation. Importantly, GATA-1 functions as a central broker in both megakaryopoiesis and erythropoiesis. In megakaryopoiesis, GATA-1 participates in complexes that promote megakaryopoiesis and also repress erythropoiesis. Conversely, in erythropoiesis, GATA-1 complexes promote erythropoiesis and repress megakaryopoiesis. It is likely that the complexes promoting megakaryopoiesis are similar to, or the same as, those that repress erythropoiesis. For example Fli-1 binding to a megakaryocytic promoter may engage neighboring GATA-1/FOG1 to potentiate activation, while Fli-1 recruitment to an erythroid promoter through tethering to EKLF or GATA-1 may exert a repressive function through its exposed DNA binding domain (see Figure 2) . Cracking the code for erythro-megakaryocytic lineage divergence will require detailed understanding of the web of functional, physical and signaling connectivity among the known players, as well as regulators yet to be named.
